Federal psychedelic medicine policy takes center stage at a Washington summit focused on regulation, access, veterans, research, and bipartisan momentum

Federal psychedelic medicine policy sits at the center of a Washington summit bringing together lawmakers, agency voices, advocates, researchers, and veterans around regulation, access, and clinical progress. Bipartisan interest, federal pathways, and the role of public institutions appear to shape the discussion. Psilocybin and MDMA are likely central reference points because they anchor much of the current U.S. policy and research landscape. Key themes include how evidence from trials could translate into medical frameworks, how veterans and mental health needs influence political urgency, and how federal agencies may respond as state-level reforms continue. The summit matters because psychedelic medicine is moving from a niche issue toward mainstream policy debate. Coordination between Congress, regulators, clinicians, and public-interest groups could determine how safety standards, access, funding, and national legitimacy develop over the next phase of adoption.